A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

The GLP-1 drug, exenatide, has no positive impact ... The world's largest and longest trial of exenatide in people with Parkinson's disease was funded by the National Institute for Health ...

With GLP-1 shortage issue largely resolved, continued growth in this category is expected, although direct-to-consumer channels may complicate efforts to track usage trends. Overall U.S. drug ...

Background Recent research on Parkinson's disease (PD) therapy has highlighted glucagon-like peptide 1 (GLP-1) agonists as potential therapeutic agents. However, recent randomized controlled trials ...

Capsida Biotherapeutics ("Capsida") today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for CAP-003, its potential best-in-class ...

Yet experts say we may be entering the golden years of Parkinson ... disease in the U.S. alone. That’s twice the prevalence four decades ago, and researchers predict the number will rise to over ...

People who followed the MIND diet -- a combination of the Mediterranean diet and the Dietary Approaches to Stop Hypertension ...

The implications of the study are encouraging, given that cigarette smoking is the leading cause of preventable disease and death in the U.S. "GLP-1 receptor agonists may offer a promising path to ...

An estimated 1.1 million people in the United States are living with Parkinson's disease, a progressive brain disorder characterized by tremors, slowness of movement, limb stiffness, and gait and ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...